Cannabis Law Report

AUGUST 9, 2021

The patent will be in force until July 14, 2040. The development of additional forms of administration and swallowable products constitutes a significant breakthrough, as they enable access to cannabis-based treatments for new patient populations who are not interested in consuming the products that currently exist on the market.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment Patients 98

Cannabis Law Report

NOVEMBER 12, 2021

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

MAY 6, 2022

Arcus Plant Growth Regulator for Seed Treatment. Phone: 360-902-2040. Products Removed from the List: A review found that the labeled uses did not meet WSDA criteria: Type. EPA or WA Registration Number. Merus 3.0*. Valley-phite. Section 25b. 994150-21001. Email for fertilizer registration: fertreg@agr.wa.gov.

THC 52

THC Concentrates Seed-To-Sale Cannabis 52

Cannabis Law Report

OCTOBER 26, 2021

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52